Transarterial hepatic yttrium-90 radioembolization for treatment of unresectable intrahepatic cholangiocarcinoma
Record ID 32013000288
English
Authors' recommendations:
Cholangiocarcinomas are malignancies of the biliary tract that can be either intrahepatic or extrahepatic. These cancers are rare and account for fewer than 3% of the malignancies in the United States. The 5-year survival rate is approximately 30% to 40% for intrahepatic cancers after resection with curative intent. However, cholangiocarcinomas are typically diagnosed at an advanced stage of disease and only 10% of the cases are eligible for curative resection. For patients receiving palliative care, the median survival duration is fewer than 6 months. Chemotherapy alone has minimal effects on local tumor control and on survival, and is more efficacious when combined with radiotherapy, or when used as a neoadjuvant to reduce tumor size and allow surgical resection. External radiotherapy can have a palliative effect; however, it carries the risk of radiation toxicity to healthy liver tissue.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=14675
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Angiography
- Yttrium Radioisotopes
- Liver Neoplasms
- Embolization, Therapeutic
- Cholangiocarcinoma
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2012 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.